REVMATOLOGICK STAV
A United Kingdom buyer, with 6 published contracts, worth £263.6m, most recently 6 months ago.
Top 3 suppliers won 100% of awarded value — £263.6m of £263.6m across 6 awards.
This contract involves the ongoing supply of specific medications as outlined in Appendix 1 of the Purchase Agreement – Price Offer. The required medications include methotrexate (L04AX03), leflunomide (L04AA13), and hydroxychloroquine (P01BA02). Suppliers must adhere to the procurement conditions a
This contract involves the ongoing supply of the medication Certolizumab (L04AB05) as detailed in Appendix 1 of the Purchase Agreement – Price Offer. Suppliers are expected to deliver the medication in accordance with the specified procurement conditions.
This contract involves the ongoing supply of medications as outlined in Appendix 1 of the Purchase Agreement – Price Offer. The supplies must include the pharmaceutical product Denosumab (M05BX04) in accordance with the tender conditions.
This contract involves the ongoing supply of the medication Etanercept (L04AB01) as detailed in Appendix 1 of the Purchase Agreement – Price Offer. Suppliers are expected to deliver these pharmaceutical products in accordance with the specified procurement conditions.
This contract involves the ongoing supply of the medication Belimumab (L04AA26) as detailed in Appendix 1 of the Purchase Agreement – Price Offer. Suppliers are expected to deliver the medication in accordance with the specified procurement conditions.
This contract involves the ongoing supply of the medication Denosumab (M05BX04) as detailed in Appendix 1 of the Purchase Agreement - Price Offer. Suppliers are expected to deliver the specified pharmaceutical product in accordance with the tender conditions.
